Trials / Completed
CompletedNCT00838838
Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis
Nebido® Therapy in Hypogonadal Male Patients With Osteoporosis Associated With Paraplegia Compared With Conventional Osteoporosis - Prophylaxis / Therapy in Hypogonadal and Eugonadal Patients With Osteoporosis Associated With Paraplegia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 26 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Both conditions hypogonadism and immobilisation (paraplegia) may contribute or lead to decreased bone mineral density resp osteoporosis. In this study bone mineral density is assessed in hypogonadal paraplegic patients, who are on standard prophylactic therapy for osteoporosis and and on a standard physiotherapy exercise program one group receiving Nebido for testosterone replacement (TRT). The additional effect of TRT on bone mineral density / osteoporosis is assessed (CT scan lumbar spine).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Testosterone Undeconate (Nebido-R, BAY86-5037) | Male patients \> 18yrs in medical practices fulfilling all criteria for documentation. |
Timeline
- Start date
- 2005-09-01
- Primary completion
- 2009-05-01
- Completion
- 2009-05-01
- First posted
- 2009-02-06
- Last updated
- 2010-04-14
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00838838. Inclusion in this directory is not an endorsement.